This clinical trial is focused on patients with end-stage renal disease who are candidates for a kidney transplant. The study is investigating the effects of a medication called Eplerenone, which is a type of drug known as a mineralocorticoid receptor blocker. This medication will be compared to a placebo to see how it affects kidney function after transplantation. The main goal is to understand how Eplerenone impacts the kidney’s ability to filter blood, which is measured by something called the glomerular filtration rate, three months after the transplant.

Participants in the study will receive either Eplerenone or a placebo for four days before and immediately after their kidney transplant. The study will monitor various aspects of kidney health and overall well-being, including the clearance of a substance called Iohexol at three months, which helps assess kidney function. Other factors being observed include the need for dialysis, the occurrence of delayed graft function, protein levels in urine, and any episodes of high potassium levels, known as hyperkalemia, within the first week after the transplant.

The study will also track the length of the initial hospital stay, the survival rate of patients, and the kidney’s filtration rate over time, up to ten years after the transplant. Additionally, the occurrence of any acute rejection of the transplanted kidney will be recorded. This research aims to provide valuable insights into improving long-term outcomes for kidney transplant recipients.